Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|February 14, 2025

A case of a mother experiencing PPD while on low-dose SSRI

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how a mother's persistent PPD symptoms despite SSRI treatment necessitated a comprehensive reevaluation of medication dosage, additional therapeutic interventions, and closer monitoring of treatment response to achieve better symptom control.

Episodes in this series

1 expert is featured in this series.

EP. 1 Overview of Postpartum Depression

1 expert is featured in this series.

EP. 2 Real-World Patient Perspective: Navigating Care for PPD

1 expert is featured in this series.

EP. 3 Real-World Patient Perspective: Breaking the Stigma of PPD and Seeking Support

1 expert is featured in this series.

EP. 4 Diagnostic Tools For PPD

1 expert is featured in this series.

EP. 5 Current and emerging treatments for PPD

1 expert is featured in this series.

EP. 6 A case of a mother experiencing PPD at 12 weeks postpartum

1 expert is featured in this series.

EP. 7 Treatment approach for a mother experiencing PPD at 12 weeks postpartum

1 expert is featured in this series.

EP. 8 A case of a mother experiencing PPD while on low-dose SSRI

1 expert is featured in this series.

EP. 9 Treatment approach for a mother experiencing PPD already on SSRI

postpartum depression

EP. 10 Panel Discusses Screening, Treatment, and Challenges for Postpartum Depression

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia

FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease

DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial

Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety

Brain Trust: Carl Salzman, MD, on Benzodiazepine Mindful Prescribing, Misuse, and Dependence